St. Jude Medical Inc.
) is set to announce its 2014-first quarter results on April 16.
In the last quarter, the company posted a positive surprise of
3.1%. Let's see how things are shaping up for this announcement.
Growth Factors This Past Quarter
St. Jude Medical posted a 7.6% rise in adjusted net earnings per
share to 99 cents for the fourth quarter of 2013 from 92 cents a
year-ago and beat the Zacks Consensus Estimate by 3 cents.
Revenues grew 3.6% to $1,422 million for the quarter, exceeding
the Zacks Consensus Estimate of $1,381 million. Unfavorable
foreign currency translation reduced revenues by roughly $27
For the first quarter of 2014, St. Jude Medical expects revenues
in the range of $1,280 to $1,360 million while the company
anticipates adjusted net earnings per share to lie between 94 and
96 cents for the quarter. The current Zacks Consensus Estimates
for earnings per share and revenues for the quarter are pegged at
96 cents and $1,356 million.
For full year 2014, St. Jude Medical anticipates revenues in the
range of $5,600 million to $5,750 million and adjusted net
earnings per share between $3.94 and $3.99. The current Zacks
Consensus Estimates for earnings per share and revenues for the
year are pegged at $3.98 and $5,693 million.
Our proven model does not conclusively show that St. Jude Medical
is likely to beat earnings this quarter. That is because a stock
needs to have both a positive Earnings ESP and a Zacks Rank of
#1, 2 or 3 for this to happen. That is not the case here as you
will see below.
, the difference between the Most Accurate estimate of 95 cents
and the Zacks Consensus Estimate of 95 cents, stands at nil.
Zacks Rank #2 (Buy):
The combination of St. Jude Medical's Zacks Rank #2 (Buy) and 0%
ESP makes surprise prediction difficult. We caution against
stocks with Zacks #4 and #5 Ranks (Sell rated stocks) going into
the earnings announcement, especially when the company is seeing
negative estimate revisions momentum.
Other Stocks to Consider
Here are some other companies you may want to consider as our
model shows they have the right combination of elements to post
an earnings beat this quarter:
BAXTER INTL (BAX): Free Stock Analysis Report
EDWARDS LIFESCI (EW): Free Stock Analysis
OMEROS CORP (OMER): Free Stock Analysis
ST JUDE MEDICAL (STJ): Free Stock Analysis
To read this article on Zacks.com click here.
Baxter International Inc.
), Earnings ESP of 7.3% and Zacks Rank #3 (Hold)
Edwards Lifesciences Corp.
), Earnings ESP of 1.5%and Zacks Rank #3 (Hold)
), Earnings ESP of 8.9% and Zacks #3 Rank (Hold)